As of close of business last night, Arcturus Therapeutics Holdings Inc’s stock clocked out at $29.31, down -3.68% from its previous closing price of $30.43. On the day, 609594 shares were traded.
Ratios:
To gain a deeper understanding of ARCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $90.
On July 24, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $71.
H.C. Wainwright Upgraded its Neutral to Buy on May 11, 2023, whereas the target price for the stock was revised from $19 to $51.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’24 when Chivukula Pad sold 17,435 shares for $35.02 per share. The transaction valued at 610,574 led to the insider holds 473,448 shares of the business.
Chivukula Pad sold 8,565 shares of ARCT for $299,839 on Mar 19 ’24. The Chief Scientific Officer & COO now owns 490,883 shares after completing the transaction at $35.01 per share. On Nov 01 ’23, another insider, Chivukula Pad, who serves as the Chief Scientific Officer & COO of the company, sold 5,000 shares for $18.72 each. As a result, the insider received 93,602 and left with 499,448 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.90 while its Price-to-Book (P/B) ratio in mrq is 2.82.
Stock Price History:
Over the past 52 weeks, ARCT has reached a high of $43.81, while it has fallen to a 52-week low of $17.52.
Shares Statistics:
A total of 26.83M shares are outstanding, with a floating share count of 24.56M. Insiders hold about 8.75% of the company’s shares, while institutions hold 90.13% stake in the company.
Earnings Estimates
As of right now, AdvisorShares Vice ETF analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $20.24, with high estimates of $29.31 and low estimates of $10.09.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Financial Services.
